Rep. Matsui Introduces Bipartisan Bill to Require Drug Makers to Disclose Ingredient Sources
The Drug Origin Transparency Act of 2026 is currently in the early stages of the legislative process. It was recently introduced and sent to the House Committee on Energy and Commerce for review. The bill is actively moving as it waits for the committee to consider it.
Part of: story →This bill has support from both Democrats and Republicans, which helps its chances. However, many bills about drug regulations take a long time to move through the House.
Small pharmaceutical manufacturers and compounding pharmacies would face new paperwork burdens, including more frequent reporting of supply chain details and updating labels to include original manufacturer information. While larger companies can absorb these compliance costs more easily, smaller operations may find the added reporting (up to four times per year) and labeling changes more burdensome relative to their resources.
“be submitted more frequently than annually, in accordance with a reporting schedule as may be specified by the Secretary in such regulation or guidance, but not more frequently than 4 times per year”
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
Congresswoman Doris Matsui and a bipartisan group introduced the Drug Origin Transparency Act of 2026. The bill requires drug companies to report specific supplier details for active ingredients and mandates labels to identify the original manufacturing factory to improve supply chain visibility.
Legislation introduced by Reps. Matsui, Crenshaw, Hinson, and Schrier aims to strengthen oversight of the pharmaceutical supply chain. The Act empowers the FDA to require detailed reporting on ingredient suppliers and mandates that drug labels identify all manufacturers involved in production.
Medical professionals are advocating for the Drug Origin Transparency Act to address persistent drug shortages. The policy would require manufacturers to file quarterly reports on supplies and ingredient sources, providing the FDA with critical data to anticipate and mitigate supply disruptions.
Document Type
Congressional Bill
Official Title
Drug Origin Transparency Act of 2026
Analysis generated by AI. Always verify with official sources.